RBT contracted Medicus Research, a contract research organization for the dietary supplement, functional foods and botanical drug industries, to perform a comprehensive analysis of independent studies conducted on behalf of RBT to substantiate numerous health claims for its proprietary and process patented rice bran derivatives and products.
According to RBT, the research from Medicus substantiated that RiBran and RiSolubles products reduce hyperglycemia; improve insulin levels and insulin sensitivity; and increase adiponectin levels. The research also cited scientific evidence indicating that the company's RiFiber product reduces total cholesterol, LDL cholesterol and triglycerides; reduces absorption of cholesterol; and reduces plasma lipid and lipoprotein cholesterol.
The full report as well as links to clinical study findings can be found at www.ricebrantech.com.
W. John Short, CEO and president of RBT commented, "As the consumer package goods industry focuses billions of dollars on healthy whole food nutrition, the ability to provide ingredients that can result in important front of label claims for these new products differentiates RBT from our competitors. Medicus Research is widely considered to be the leading provider of research and clinical trials for healthy, natural products and functional foods. We are excited that the team at Medicus has substantiated the health benefits of our rice bran based products. We plan to pursue additional studies with Medicus going forward."
Dr. Jay Udani, co-founder and CEO of Medicus Research noted, "RiceBran Technologies proprietary ingredients and the active components of these ingredients have been the subject of numerous studies which, when the evidence is combined, appear to be able to substantiate claims related to the management of healthy lipids, glucose, and insulin. We look forward to working with RBT on additional projects in the future."